论文部分内容阅读
目的：研究中国子宫内膜癌患者的瘤组织中Ｋｒａｓ基因第１外显子（含第１２，１３密码子）的突变率，以及突变与子宫内膜癌临床情况的关系，探讨Ｋｒａｓ基因突变在子宫内膜癌发生中的作用。方法：３７例子宫内膜癌的石蜡和部分冰冻标本行ＰＣＲ扩增Ｋｒａｓ基因第１外显子（含第１２，１３密码子），经ＰＣＲＳＳＣＰ银染法检测突变。结果：３７例子宫内膜癌患者中有１２例存在Ｋｒａｓ基因突变，突变率为３２．４％（１２／３７例）。ＦＩＧＯ分期Ⅲ期、组织类型为腺鳞癌的患者突变率较高，在细胞低分化、侵肌１／２以上和绝经后的患者中突变比例也较高。石蜡和冰冻组织标本结果一致。结论：Ｋｒａｓ基因突变率在日、美两国内膜癌患者中不同。该组患者中的突变率与日本相似，高于美国。说明此种差异不仅存在于日本和美国患者之间，可能也存在于亚洲人与北美洲人之间。不同的基因背景，生活条件及内源性和外源性雌激素作用可能对Ｋｒａｓ基因突变率有影响，并引起了不同的临床表现。
Objective: To study the mutation rate of exon 1 (including codon 12 and 13) of K-ras gene in the tumor tissue of Chinese patients with endometrial carcinoma and the relationship between the mutation and the clinical situation of endometrial carcinoma, Role of ras gene mutation in the development of endometrial. Methods: 37 cases of endometrial cancer paraffin and some frozen specimens PCR amplification K ras gene exon 1 (including the first 12,13 codons), by PCR SSCP silver staining detection of mutations. Results: 37 cases of endometrial cancer in 12 cases there K Kras mutation, the mutation rate was 32.4% (12/37 cases). FIGO stage Ⅲ, the type of adenosquamous carcinoma patients with higher mutation rate, cell differentiation in the poor, more than 1/2 invaders and postmenopausal patients with higher mutation rates. Paraffin and frozen tissue specimens consistent. Conclusion: K-ras gene mutation rate in Japan and the United States two different endometrial cancer patients. The mutation rate in this group of patients is similar to that of Japan and higher than that of the United States. This difference shows not only exists between Japan and the United States patients, may also exist between Asians and North Americans. Different genetic backgrounds, living conditions and the role of endogenous and exogenous estrogen may affect the mutation rate of K-ras gene and cause different clinical manifestations.